Cargando…
Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
Blocking IL-6 pathways with sarilumab, a fully human anti–IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used “off-label” sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We sugg...
Autores principales: | Corominas, Hèctor, Castellví, Ivan, Diaz-Torné, César, Matas, Laia, de la Rosa, David, Mangues, Maria Antònia, Moya, Patricia, Pomar, Virginia, Benito, Natividad, Moga, Ester, Sosa, Nerea Hernandez-de, Casademont, Jordi, Domingo, Pere |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133253/ https://www.ncbi.nlm.nih.gov/pubmed/34106658 http://dx.doi.org/10.1097/MD.0000000000025923 |
Ejemplares similares
-
The four horsemen of a viral Apocalypse: The pathogenesis of SARS-CoV-2 infection (COVID-19)
por: Domingo, Pere, et al.
Publicado: (2020) -
Not all COVID-19 pandemic waves are alike
por: Domingo, Pere, et al.
Publicado: (2021) -
Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study
por: Castellví, Ivan, et al.
Publicado: (2022) -
Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19
por: Benito, Natividad, et al.
Publicado: (2020) -
Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
por: Sainz, Luis, et al.
Publicado: (2023)